CClinicalTrials.gg
RecruitingNCT05255536Updated Feb 2, 2024

Effect of Different Local Anesthetic Volumes of Serratus Anterior Plan Block After Video-Assisted Thoracoscopic Surgery

An interventional study of Serratus Anterior Plan Block with 20 ml and Serratus Anterior Plan Block with 30 ml in Serratus Anterior Plane Block, Pain, Postoperative and Thoracic Surgery, Video-Assisted, sponsored by Atatürk Chest Diseases and Chest Surgery Training and Research Hospital. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by Atatürk Chest Diseases and Chest Surgery Training and Research Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Feb 2022; still recruiting 4 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Video-assisted thoracic surgery (VATS) has become a common procedure in thoracic surgery. Severe postoperative pain may be encountered in patients undergoing VATS. Analgesic methods such as thoracic paravertebral block (TPVB), intercostal block, serratus anterior plane block (SAPB), and erector spinae plane block (ESPB) are widely used for VATS. Among these methods, ultrasound (US) guided TPVB is the most preferred method. In recent years, the frequency of application of plane blocks as a component of multimodal analgesia has been increased. ESPB and SAPB are some of them. In addition, SAPB application is increasing in patients who underwent thoracotomy and VATS. There is no consensus on the dose of analgesia in these studies. There are studies on volumes between 10 ml and 40 ml in the literature. In this study, it was aimed to compare the volumes of 20 ml and 30 ml containing local anesthetic at the same concentration (0.25% bupivacaine) of SAPB block to be performed with USG in patients who underwent VATS.

02

Conditions studied

  • Serratus Anterior Plane Block
  • Pain, Postoperative
  • Thoracic Surgery, Video-Assisted
  • Local Anesthetic

Browse trials for

03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's planned enrollment of 60 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Atatürk Chest Diseases and Chest Surgery Training and Research Hospital is the lead sponsor of 28 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 to 65 years old
  • ASA physical status I-II-III
  • BMI 18 to 30 kg/m2
  • Elective video assisted thoracoscopic surgery

Exclusion criteria

Exclusion Criteria:

  • Patient refusing the procedure
  • Emergency surgery
  • Chronic opioid or analgesic use
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Serratus Anterior Plan Block with 20 ml %0.25 Bupivacaine

    Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.

    Procedure: Serratus Anterior Plan Block with 20 ml

  • Active comparator
    Serratus Anterior Plan Block with 30 ml %0.25 Bupivacaine

    Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 30 ml 0.25% bupivacaine will be injected into the area.

    Procedure: Serratus Anterior Plan Block with 30 ml

Interventions

  • ProcedureSerratus Anterior Plan Block with 20 ml

    Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.

    Also known as: Drug

  • ProcedureSerratus Anterior Plan Block with 30 ml

    Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.

    Also known as: Drug

06

What researchers measure

Primary outcomes

  1. Pain Scores

    Pain will be assessed at rest and while coughing using the visual analog scale on a scale from 0 (no pain) to 10 (worst pain). Pain assessment will be done at 1st, 2nd, 4th, 8th, 16th, 24th and 48th hours after surgery.

    Time frame: 48 hours after surgery

Secondary outcomes

  1. Morphine Consumption

    Morphine consumption for 24 hours will be recorded

    Time frame: 24 hours after surgery

07

Study locations

1 of 1 sites recruiting
  • Ankara Atatürk Chest Disease and Chest Surgery Training and Research Hospital
    Kecioren, Ankara 06000, Turkey
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05255536
Lead sponsor
Atatürk Chest Diseases and Chest Surgery Training and Research Hospital
Responsible party
Musa Zengin (Principal İnvestigator, Atatürk Chest Diseases and Chest Surgery Training and Research Hospital) — Principal investigator
First posted
Feb 24, 2022
Start date
Feb 15, 2022
Primary completion
Apr 15, 2024 (estimated)
Completion
May 15, 2024 (estimated)
Last update
Feb 2, 2024

Study contacts

Musa Zengin, MD
Contact
musazengin@gmail.com
903125677233
Ali Alagoz, Assoc Prof
Contact
mdalagoz@gmail.com
+903125677232
Musa Zengin, MD
principal investigator · Atatürk Chest Diseases and Chest Surgery Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion